TG Therapeutics (TGTX) Key Ratios

$53.92

up-down-arrow $-1.47 (-2.65%)

As on 11-Sep-2026 13:35EDT

Market cap

info icon

$8,570 Mln

Revenue (TTM)

info icon

$800 Mln

P/E Ratio

info icon

20.4

P/B Ratio

info icon

14.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 17.28 70.27 76.08 221.54 219.17
EBIT -- -- 15.19 38.94 18.45
Net Profit -60.66 -72.40 630.24 65.26 26.83
EPS -59.96 -71.47 633.67 60.91 24.64
Book Value -- -- 193.03 111.91 -0.57
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 15.94-2,548.4714.0421.7615.08
Net Margin info ---3,869.5155.22----
Return on equity info 42.18-23.3770.52102.7512.21
Return on Capital info 25.66-20.03--64.586.26
Return on Assets info 21.50-16.5731.7354.505.15
Debt to Equity (x) info ----1.230.401.14
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
--
64.58
6.26
6.14
-97.77
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

70.52

Higher than Peers by 110.85

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
70.52
102.75
12.21
11.57
-151.36
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

31.73

Higher than Peers by 62.98

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
31.73
54.50
5.15
4.84
-78.09
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

14.04

Higher than Peers by 96.64

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
14.04
21.76
15.08
10.99
-7,670.41
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

55.22

Higher than Peers by 146.52

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
55.22
72.56
7.11
5.42
-8,036.34
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Higher than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

76.08

Higher than Peers by 22.05

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
76.08
0.87
0.41
82.90
-0.58
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

15.19

Higher than Peers by 16.21

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
15.19
170.28
93.25
112.02
37.62
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

630.24

Higher than Peers by 637.78

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
630.24
1,812.41
84.52
105.66
35.70
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

633.67

Higher than Peers by 619.44

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
633.67
18.23
0.65
1.05
0.38
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

125.86

Higher than Peers by 135.99

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
125.86
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

1.23

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
1.23
0.40
1.14
0.69
1.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
0.00
0.00
0.01
0.01
0.03
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.27

Lower than Peers by 1.54

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
4.27
4.10
6.25
5.92
3.16
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.72

Lower than Peers by 1.98

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
3.72
3.29
5.03
5.18
3.16
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

3.71

Higher than Peers by 5.80

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
3.71
5.02
2.07
2.04
-20.96
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

50.22

Higher than Peers by 31.21

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
50.22
49.59
39.27
21.87
--
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.57

Higher than Peers by 0.51

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
0.57
0.75
0.73
0.89
0.01
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
--
128.85
100.07
39.93
91.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
--
428.02
713.12
514.66
-16,266.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
--
300.65
459.18
1,040.23
64,306.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
--
256.22
354.01
-485.64
-80,482.38
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

20.43

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
20.43
10.62
206.28
192.87
-7.25
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

14.42

Higher than Peers by 9.09

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
14.42
7.33
21.69
15.23
27.69
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

63.93

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
63.93
36.24
95.51
89.55
-7.24
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

8,570

Higher than Peers by 8,429

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
TG Therapeutics (TGTX)
8,570
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...